Lv4
538 积分 2023-01-12 加入
Drug resistance in breast cancer: Mechanisms and strategies for management
8天前
已完结
EGFR在不同分子分型乳腺癌中的表达及其与临床病理指标的关系
8天前
已完结
Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis
8天前
已完结
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
8天前
已完结
Immune marker expression and prognosis of early breast cancer expressing HER3
8天前
已完结
Can EGFR be a therapeutic target in breast cancer?
8天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
21天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
21天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
23天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
28天前
已完结
皖公网安备34019202002308
